Perfectus Biomed seals £100k growth funding
A FLEDGLING medical testing company has secured £100,000 investment to expand its research team and make other strategic investments.
Perfectus Biomed, based at Sci-Tech Daresbury, Cheshire, received £50,000 from The North West Fund for Biomedical, managed by SPARK Impact, and another £50,000 from venture capital company Midven.
Perfectus Biomed specialises in the microbiological testing of biofilm- encased bacteria. Persistent biofilm infections have been linked to chronic non-healing wounds, failed medical implants and catheter infections.
The company carries out microbiological testing to help its clients develop anti-microbial and anti-biofilm agents and devices suitable for use in areas including woundcare, medical implants, dentistry and contact lenses.
The funding will be used by Perfectus Biomed to grow its research team, undertake a marketing strategy across the UK and in Europe, and to invest in IT and internal management systems.
Dr Samantha Westgate, business and scientific director of Perfectus Biomed, said: “We are delighted to receive this investment. It will support the growth and development of Perfectus Biomed, enabling us to increase employee numbers and drive our exciting expansion into new sectors.”
Dr Penny Attridge, senior investment director at SPARK Impact and manager of The North West Fund for Biomedical, said: “Perfectus Biomed has developed a novel research based approach to microbiological testing and we’re pleased to support the firm in its growth plans.
“Its work supports key medical sectors and we believe it to be a huge asset to SPARK’s biomedical portfolio.”
Dr Andrew Muir, director of Midven added: “The importance of biofilm testing is being increasingly recognised across the consumer and medical device sectors and Perfectus is uniquely poised to take advantage of this.”
